Drugs / MT-8421
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06034860 | Nov 2023 → Oct 2024 | cervical cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma +5 | Molecular Templates, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-8421 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06034860 ↗ |
| Action | Deplete | “specifically targets and depletes cytotoxic T-lymphocytes-associated protein 4 (CTLA-4) expressing cells” NCT06034860 ↗ |
| Modality | Protein / enzyme biologic | “MT-8421 (an Engineered Toxin Body (ETB))” NCT06034860 ↗ |
| Route | Intravenous | “MT-8421 will be given as an intravenous (IV) infusion” NCT06034860 ↗ |